JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Home・Akcijų sąrašas・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

511.87 -1.1

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

504.99

Max

521.24

Pagrindiniai rodikliai
By Trading Economics
Pajamos	56M -59M
Pardavimai	34M 321M
Pelno marža	-18.243
Darbuotojai	915
EBITDA	56M -50M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+28.32% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	1.5B 12B
Ankstesnė atidarymo kaina	512.97
Ankstesnė uždarymo kaina	511.87

Naujienos nuotaikos

By Acuity

92%

39 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

263.2 / 277.1 Palaikymas ir pasipriešinimas

Madrigal Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-24 19:19; UTC

Įsigijimai, susijungimai, perėmimai

Intertek Group Rejects EQT's Revised Offer

2026-04-24 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Scoring the Cook Era -- Barrons.com

2026-04-24 20:51; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-04-24 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-24 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 20:09; UTC

Uždarbis

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

2026-04-24 19:48; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

2026-04-24 19:25; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 19:25; UTC

Įsigijimai, susijungimai, perėmimai

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

2026-04-24 19:22; UTC

Uždarbis

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

2026-04-24 19:06; UTC

Uždarbis

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

2026-04-24 19:05; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

2026-04-24 18:30; UTC

Įsigijimai, susijungimai, perėmimai

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

2026-04-24 18:28; UTC

Įsigijimai, susijungimai, perėmimai

Intertek Rejects Revised EQT Offer

2026-04-24 18:12; UTC

Rinkos pokalbiai

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

2026-04-24 18:06; UTC

Rinkos pokalbiai

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

2026-04-24 17:42; UTC

Uždarbis

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

2026-04-24 17:28; UTC

Uždarbis

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

2026-04-24 17:28; UTC

Rinkos pokalbiai

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

2026-04-24 17:12; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-24 17:11; UTC

Rinkos pokalbiai

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

2026-04-24 17:09; UTC

Rinkos pokalbiai

Uždarbis

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

2026-04-24 17:09; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 17:06; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

2026-04-24 16:51; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

2026-04-24 16:20; UTC

Rinkos pokalbiai

Uždarbis

Tech, Media & Telecom Roundup: Market Talk

2026-04-24 16:20; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-04-24 16:20; UTC

Rinkos pokalbiai

Uždarbis

Auto & Transport Roundup: Market Talk

2026-04-24 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

Akcijų palyginimas

Kainos pokytis

Madrigal Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

28.32% į viršų

12 mėnesių prognozė

Vidutinis 665.67 USD 28.32%

Aukščiausias 964 USD

Žemiausias 529 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Madrigal Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Madrigal Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

263.2 / 277.1Palaikymas ir pasipriešinimas

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Rinkos nuotaikos

By Acuity

39 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.